Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Tepotinib for Metastatic Non-Small Cell Lung Cancer

Conversion to traditional approval is based on an additional patients and an added follow-up time to assess duration of response in the VISION study
20 Feb 2024
Targeted Therapy;  Molecular Oncology
Non-Small Cell Lung Cancer

On 15 February 2024, the US Food and Drug Administration (FDA) granted traditional approval to tepotinib (Tepmetko, EMD Serono, Inc.) for adult patients with metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

Tepotinib was previously granted accelerated approval for this indication on 3rd February 2021, based on initial overall response rate (ORR) and duration of response (DoR) in the VISION study (NCT02864992), a multicentre, non-randomised, open-label, multicohort study. The conversion to traditional approval was based on an additional 161 patients and an added 28 months of follow-up time to assess DoR.

Efficacy was demonstrated in a total of 313 patients with metastatic NSCLC harbouring MET exon skipping alterations. Patients received tepotinib 450 mg once daily until disease progression or unacceptable toxicity.

The primary efficacy measures were ORR and DoR, determined by a Blinded Independent Review Committee. Among 164 treatment-naïve patients, ORR was 57% (95% confidence interval [CI] 49, 65), with 40% of responders having a DoR ≥12 months. Among 149 previously treated patients, ORR was 45% (95% CI 37, 53), with 36% of responders having a DoR ≥12 months.

The most common adverse reactions (≥20%) were oedema, nausea, fatigue, musculoskeletal pain, diarrhoea, dyspnoea, decreased appetite, and rash.

The recommended tepotinib dose is 450 mg orally once daily with food.

This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.

This application was granted breakthrough designation and orphan drug designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.